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Summary
Background Although the co-benefits from addressing problems related to both climate change and air pollution have 
been recognised, there is not much evidence comparing the mitigation costs and economic benefits of air pollution 
reduction for alternative approaches to meeting greenhouse gas targets. We analysed the extent to which health co-
benefits would compensate the mitigation cost of achieving the targets of the Paris climate agreement (2°C and 1·5°C) 
under different scenarios in which the emissions abatement effort is shared between countries in accordance with 
three established equity criteria.
Methods Our study had three stages. First, we used an integrated assessment model, the Global Change Assessment 
Model (GCAM), to investigate the emission (greenhouse gases and air pollutants) pathways and abatement costs of a 
set of scenarios with varying temperature objectives (nationally determined contributions, 2°C, or 1·5°C) and 
approaches to the distribution of climate change methods (capability, constant emission ratios, and equal per capita). 
The resulting emissions pathways were transferred to an air quality model (TM5-FASST) to estimate the concentrations 
of particulate matter and ozone in the atmosphere and the resulting associated premature deaths and morbidity. We 
then applied a monetary value to these health impacts by use of a term called the value of statistical life and compared 
these values with those of the mitigation costs calculated from GCAM, both globally and regionally. Our analysis 
looked forward to 2050 in accordance with the socioeconomic narrative Shared Socioeconomic Pathways 2.
Findings The health co-benefits substantially outweighed the policy cost of achieving the target for all of the scenarios 
that we analysed. In some of the mitigation strategies, the median co-benefits were double the median costs at a 
global level. The ratio of health co-benefit to mitigation cost ranged from 1·4 to 2·45, depending on the scenario. At 
the regional level, the costs of reducing greenhouse gas emissions could be compensated with the health co-benefits 
alone for China and India, whereas the proportion the co-benefits covered varied but could be substantial in the 
European Union (7–84%) and USA (10–41%), respectively. Finally, we found that the extra effort of trying to pursue 
the 1·5°C target instead of the 2°C target would generate a substantial net benefit in India (US$3·28–8·4 trillion) and 
China ($0·27–2·31 trillion), although this positive result was not seen in the other regions.
Interpretation Substantial health gains can be achieved from taking action to prevent climate change, independent of 
any future reductions in damages due to climate change. Some countries, such as China and India, could justify 
stringent mitigation efforts just by including health co-benefits in the analysis. Our results also suggest that the 
statement in the Paris Agreement to pursue efforts to limit temperature increase to 1·5°C could make economic 
sense in some scenarios and countries if health co-benefits are taken into account.
Funding European Union’s Horizon 2020 research and innovation programme.
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Introduction
The two main health-harmful air pollutants linked to 
fossil fuel combustion and greenhouse gas (GHG) 
emissions are fine particulate matter (PM2·5);1–3 and 
ozone (O3).4,5 In this context, the Paris climate agreement, 
which aims to significantly reduce fossil fuel use, has 
major health implications. The agreement sets a long-
term stabilisation target of a 2°C increase and signatories 
have agreed to pursue efforts to limit the increase 
to 1·5°C.6
Concrete measures to achieve these targets have not yet 
been agreed. A key concern when evaluating different 
climate policies is their net cost, with a key component of 
overall policy cost being the associated co-benefits.7–11 We 
use the term mitigation cost to refer to the direct costs of 
reducing GHGs and policy costs to refer to the overall 
costs when any co-benefits have been taken into account 
(we do not include avoided climate damages). Co-benefits 
are defined as additional benefits related to the reduction 
of greenhouse gas emissions that are not directly related 
to climate change, such as air quality improvement, 
technological innovation, or employment creation.12
One of the key challenges related to the Paris goals is 
how to share the mitigation efforts for meeting the target. 
The greater the ambition of the mitigation objectives, the 
more difficult the distribution of targets across countries.13,14 
The current national mitigation targets reported by the 
different countries to the United Nations in their nationally 
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determined contributions (NDCs) are not enough,15 and, if 
they are not raised, a temperature increase of between 
2·9–3·4°C by the end of the century can be expected.6
The health co-benefits of mitigation have been explored 
previously. The major gaps in the current literature are a 
failure to look at co-benefits by region, which is important 
given the range of different allocations of mitigation 
burdens and the absence of an evaluation of the 
co-benefits relative to mitigation costs for the 1·5°C target. 
As such, we compared, at the global and regional levels, 
several climate mitigation scenarios in terms of air 
pollution and health impacts, and established to what 
extent the extra cost of achieving a more restrictive 




Our analysis consists of three steps. First, we used the 
Global Change Assessment Model (GCAM) to quantify 
the GHG pathways and the related mitigation costs of 
each scenario of climate target and mitigation strategy 
(where each scenario has its own GHG emission pathway). 
GCAM also reports the emissions of air pollutants in 
the different regions. We then passed this information 
to the TM5-Fast Scenario Screening Tool air quality 
source-receptor model, which translates emission levels 
into pollutant concentrations, exposure, and premature 
deaths. Finally, we monetised these effects by use of a 
term known as the value of statistical life (VSL),16,17 with 
the valuation extended to incorporate morbidity effects.18
Models
GCAM is an integrated assessment model originally 
developed by the Joint Global Change Research Institute 
and the Pacific Northwest National Laboratory. It has been 
used in most major climate and energy assessments over 
the past 20 years, including the last International Panel 
on Climate Change (IPCC) Report.19 The model is 
disaggregated into 32 geopolitical regions and operates in 
5 year time steps from 2005 to 2100. Details of the model 
and its data sources have been reported by Clarke and 
colleagues.20 GCAM provides the mitigation cost of 
different energy and climate policies for each specific 
region. It also reports the emissions of the main air 
pollutants including organic carbon, black carbon, 
nitrogen oxides, non-methane volatile organic compounds, 
carbon monoxide, and sulphur dioxide, which are the 
main precursors of PM2·5 and ozone.21 These emissions 
are calculated by applying an emission factor to each 
technology for every pollutant; consequently, the activity 
level, such as fuel consumption, drives emissions per 
period and region. Additionally, an emis sion control is also 
applied to each activity. The emission control generally 
increases as gross domestic product (GDP) increases, 
repre senting historical trends that, as income levels 
increase, more stringent pollution control measures will 
be put into place.
Research in context
Evidence before this study
We searched the literature for works related to health 
co-benefits, and found studies published between 2013 and 
2018. A substantial amount of work has been done to estimate 
the numbers of current and future premature deaths due to 
particulate matter and ozone concentration levels. Some 
studies have also presented a comparison between scenarios 
based on different climate or air quality policies and a few have 
compared the potential co-benefits with or abatement cost of 
obtaining a climate objective. The combination of integrated 
assessment and atmospheric models has also been described in 
some reports in recent years.
Added value of this study
Our study is the first, to our knowledge, to show the benefit-cost 
ratio of different climate change mitigation objectives under 
different scenarios for sharing emissions quotas between 
developed and developing countries, building on the work of 
Robiou du Pont and colleagues. Although there is some work 
that has applied similar methods to estimate mitigation costs, 
the future health implications of air pollution, and its monetary 
valuation, our study goes one important step further by using an 
integrated framework that allows a systematic comparison of 
the extent to which the health co-benefits compensate the costs 
of reducing greenhouse gas emissions under different pathways. 
Finally, we also investigated the 1·5°C target, the most ambitious 
target and an active topic in the current climate change debate.
Implications of the available evidence
Our results will contribute substantially to understanding the 
important synergies between air pollution and climate change 
control policies. The large variations in health co-benefits of 
achieving in different scenarios and countries, especially in 
India and China, might help policy makers to understand the 
benefits of adopting more ambitious climate policies or 
measures to reduce air pollution and to consider how to share 
the burden of reducing greenhouse gas emissions. The health 
co-benefits alone can justify the 2°C target at a global level. 
Increasing efforts to achieve the ambitious target of 1·5°C will 
also generate global health co-benefits that exceed mitigation 
costs, but only if the equal emission per capita approach 
in 2050 pathway is pursued. This result will be useful to inform 
the International Panel on Climate Change in its special report 
on the 1·5°C target, which is currently in preparation. Further 
work is needed, however to handle the distribution of net costs 
across regions, depending on what distribution of abatement 
effort is chosen. This is a serious challenge that the global 
community needs to address.
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To link GCAM with TM5-FASST, we downscaled the 
output of the 32 regions to the country level and then 
aggregated to the 56 TM5-FASST regions (appendix). 
TM5-FASST is a reduced-form global air quality 
source-receptor model developed by the European 
Commission’s Joint Research Centre. The name 
TM5-FASST derives from the native TM5 chemistry-
transport model from which an air quality source-
receptor model version was derived; FASST is an 
acronym of Fast Scenario Screening Tool, which refers 
to the current source-receptor version (Van Dingenen R, 
unpublished). The model analyses how the emissions of 
a source region affect receptor points (grid cells) in 
terms of concentrations, and subsequently, premature 
deaths. Given the concentration levels for each region, 
the model calculates the premature deaths derived from 
exposure to ozone and PM2·5, disaggregating by different 
causes of death (for ozone coverage is for respiratory 
disease and for PM2.5 it is for ischaemic heart disease, 
chronic obstructive pulmonary disease, stroke, lung 
cancer, and acute lower respiratory airway infections), 
defined by the GBD 2015 Risk Factors Collaborators.22 
These calculations require baseline mortality rates, 
which are taken from WHO data (Van Dingenen R, 
unpublished). More details of the data are available on 
the website of the Institute for Health Metrics and 
Evaluation and details for the calculations will be 
reported (Van Dingenen R, unpublished).
Finally, to monetise the estimated health impacts, we 
applied the VSL. VSL is the monetary value of a relative 
change in mortality risk reduction (usually taken to be in 
the range from 3/10 000 to 2/10 000). Given the absence 
of empirical studies that estimate VSL for all countries, 
procedures have been developed to transfer the results of 
existing studies to other regions, aiming to overcome 
this limitation.
In this study we used the “unit value transfer 
approach”,10,23 which is based on adjustment of the VSL 
to all countries according to their GDP and GDP growth 
rates, using the widely accepted VSL of the OECD for 
2005 as a reference. This value, according to the 
literature,23 ranges between US$1·8 and $4·5 million in 
2005. In this method, the VSL of a country c in the year t 
is defined as 
Where VSLc,t is the VSL for country c in year t; VSLOECD,2005 
is the base value; Y is the GDP per capita; b is the income 
elasticity of the VSL (the income elasticity generally used 
for the VSL ranges from 0·8 to 1·2; we applied the figure 
of 0·8 as proposed by the Organisation for Economic Co-
operation and Development [OECD]);24 and %ΔY is the 
income growth rate. Given the VSL for each region, the 
associated morbidity costs can be added to the mortality 
cost. These costs include a wide range of effects covering 
direct market costs, as well as indirect costs arising from 
disability and loss of earnings. Because there is no well 
accepted method to estimate these effects, we followed 
the OECD’s guidelines24 and took morbidity costs to be 
10% of the mortality costs.
Given that VSL is based on GDP, it places a higher 
value on human life in developed countries than in 
developing ones. Although this approach carries this 
moral dilemma, VSL is a well known and widely used 
method that enables users to analyse climate policy and 
cover health costs in a way that reflects how such costs 
are treated within different regions.
Scenarios
The scenarios have three main components: first, a 
general socioeconomic storyline represented by the 
Shared Socioeconomic Pathways (SSP) of the IPCC 
framework,25,26 second, a model quantification of that 
storyline, and, third, a set of mitigation strategies based 
on those described by Robiou du Pont and colleagues,27,28 
wherein current national mitigation targets are extended 
in accordance with different equity criteria to allocate the 
carbon budgets for different temperature stabilisation 
objectives.
The background socioeconomic conditions are a key 
element of the analysis because they provide baseline 
values for population and GDP in each country over 
time. The socioeconomic scenario that we have chosen, 
SSP2, is regarded as an intermediate framework. The 
features of SSP2 are that current trends continue with 
some progress towards the Sustainable Development 
Goals, with reductions in energy and material intensity 
consumption and a decline in fossil fuel dependency; 
the development rate is unequal between low-income 
countries, and global and in-country inequalities persist; 
the low level of investment in education prevents 
declines in population growth; and global governance 
achieves an intermediate level of environmental 
protection. Further details have been reported by Van 
Vuuren and colleagues.26
The SSP database, hosted by IIASA, provides the 
country-level population figures used by TM5-FASST and 
the GDP figures used to estimate monetised damage to 
health by VSL. Both population and GDP are also used by 
VSLc,t =VSLOECD,2005 × 
Yc,2005
YOECD,2005





Maintains current emission ratios, preserves status quo; this 
approach is also referred to as grandfathering, is not considered 
as an equitable option in terms of climate justice, and is not 
supported as such by any party
Capability CAP Capability Countries with high GDP per capita have low emissions allocations
Equal per capita EPC Equality Convergence towards equal annual emissions per person by 2040
Further details of the approaches to the equitable distribution of mitigation efforts are available online. 
IPCC=International Panel on Climate Change. GDP=gross domestic product.
Table 1: Mitigation equity approaches
For the Institute of Health 
Metrics and Evaluation website 
see http://www.healthdata.org/
For details of the equity of 
climate pledges see http://paris-
equity-check.org
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the GCAM model, combined with additional assumptions 
about the country’s economic structure, and energy and 
agricultural systems.29,30 In this study we used the SSP2 
emission factors to calculate the air pollutant emission 
trajectories as released with GCAM version 4.3. 
The mitigation strategies are divided on the basis of two 
criteria: the global temperature target and the regional 
distribution of the mitigation effort associated with each 
target. For the temperature target, in addition to a baseline 
scenario in which no climate policy is set, we chose three 
scenarios: the NDC scenario (domestic mitigation 
measures with targets set at the national level), the 
2°C stabilisation target, and the 1·5°C stabilisation target 
(both stabilisation targets are objectives for the year 2100).
Regarding the regional distribution of mitigation 
effort, Robiou du Pont and colleagues28 suggest 
five distributional approaches, of which we chose to 
investigate three. The allocation approaches that we 
selected were the constant emission ratios (CER) 
approach, the capability (CAP) approach, and the equal 
per capita (EPC) approach. Table 1 summarises the 
characteristics of these allocations. The two excluded 
allocations are ones involving very unequal allocations 
to developed countries and, moreover, require huge 
negative emissions to be realised, which we considered 
unrealistic.
In accordance with Robiou du Pont and colleagues,28 
we divided the world into five regions: China, the 
27 countries of the European Union in 2007–13 (EU-27), 
India, the USA (which together cover 60% of global 
emissions in 2015), and the rest of the world (ROW). The 
results are presented up to 2050.28
Although each scenario has a similar global carbon 
budget up to 2100, the carbon budgets up to 2050 are 
different as the criteria selected also affect the timing of 
mitigation. Figure 1 shows the notable differences in 
carbon dioxide (CO2) emissions pathways under the 
different combinations of temperature targets and 
mitigation effort distributions. In the NDC scenario, the 
emissions are reduced by around 25% compared with 
the baseline by 2050. Although substantial, this reduction 
is not sufficient to achieve the Paris climate target. 
Compared with the NDC scenario, the 2°C scenarios 
require a reduction in CO2 emissions across the five 
regions ranging from –71% to +57%. Logically, the 
reduction in the 1·5°C scenarios is greater, ranging from 
–79% to +8%, depending on the approach for sharing the 
mitigation effort (table 2).
While the restrictiveness of the climate target is an 
important factor in explaining the variations, the 
distributional approach is also important. As figure 1 
shows, the reduction in emissions up to 2050 is greatest 
under the CAP scenario and least under the CER 
scenario. These differences translate into different 
mitigation efforts for the different regions.
It is notable that, for the 2°C target, China has to make 
a further 69% reduction under the CAP scenario, but 
only 35% under the CER scenario. The CER scenario 
imposes the greatest burden on India, and allows the 
USA and the EU-27 to reduce emissions by 57% and 
34% less, respectively, than they have committed to 
under the NDCs (table 2).
Figure 1: Total CO2 emissions per period and scenario
CO2=carbon dioxide. NDCs=nationally determined contributions. CAP=capability scenario. CER=constant emission 
ratios scenario. EPC=equal per capita scenario.







































China –69% –35% –52% –75% –54% –65%
USA –40% 57% –16% –52% 8% –37%
EU-27 –43% 35% –4% –55% –7% –31%
India –60% –71% –36% –72% –79% –58%
ROW –50% –47% –46% –64% –63% –62%
Total –55% –35% –42% –67% –55% –59%
CAP=capability scenario. CER=constant emission ratios scenario. EPC=equal per 
capita scenario. EU-27=the 27 countries of the European Union in 2007–13. 
ROW=the rest of the world.
Table 2: Variation in 2020–50 cumulative emissions relative to the 
nationally determined contributions scenario
Figure 2: Cumulative premature deaths per region and scenario, 2020–50
NDCs=nationally determined contributions. CAP=capability scenario. CER=constant emission ratios scenario. EPC=equal 
per capita scenario. EU-27=the 27 countries of the European Union in 2007–13. ROW=the rest of the world.
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Results 
Figure 2 shows the cumulative premature deaths 
from 2020–50 for each scenario. Globally, this cumulative 
number decreases substantially between the reference 
scenario and the scenarios using the 2°C and 
1·5°C targets. In the NDC scenario, the number of deaths 
decreases by around 5% relative to the reference, whereas 
the reductions for the mitigation scenarios are from 
21–27% for the 2°C target and from 28–32% for the 
1·5°C target.
It is noticeable that the results for each region relative 
to the others are similar, irrespective of the scenario 
analysed. The largest proportions of premature deaths 
are in China (33–37% of the global deaths) and India 
(24–32%). About 37% of the global population lives in 
China and India and many of these people are exposed to 
pollution levels far above those recommended by WHO.
The mitigation costs for the defined scenarios (excluding 
the baseline scenario, which is not supposed to have any 
policy cost) and regions are shown in table 3. Under the 
CAP scenarios, China bears most of the cost, followed by 
the ROW, whereas India has the lowest share of the cost. 
However, the ranking changes substantially in the CER 
scenarios, with India now having a much greater share 
and China much smaller one. Generally, compared with 
what countries have committed to under the NDCs, the 
increases in costs are smallest for the USA and EU-27 and 
largest for the ROW, India, and China, in that order. 
Overall, the additional cost of going from a 2°C target to a 
1·5°C target is around 20%.
The absolute costs of achieving the NDCs are around 
$7·5 trillion, the majority of which will be spent in the 
USA (66%) and EU-27 (29%). Mitigation costs are highest 
under the CAP scenarios as this approach requires the 
greatest short-term reductions in emissions: the cost of 
the 2°C + CAP scenario is 45% less than the cost under 
CER and 80% higher than the cost under EPC. When 
comparing the 1·5°C scenarios, the cost of the 1·5°C + CAP 
scenario is around 40% greater than that obtained with 
the other criteria.
From a macroeconomic perspective, these costs are 
relatively low. For the 2°C target, the global costs range 
from 0·5% to 1% of global GDP, whereas for the 
1·5°C target, the range is 1% to 1·3%. Between these 
scenarios, the lowest costs emerge under the CER or 
EPC scenarios and the highest ones under the CAP 
scenario. These numbers are in line with those reported 
in the fifth IPCC assessment report,30 in which the values 
for different years for the 2°C scenario range from 
around 0% to 2% of global GDP.
A discount rate is a factor that converts anticipated 
returns from an investment project in different time 
periods to their present value. Our results are based on 
a discount rate of 3%, which is in the middle of the 
range used in the literature to discount climate 
effects.31–33 As a sensitivity test, we also used values of 





















































































Regions are ordered according to their income per capita. Percentages are the proportion of global mitigation cost borne by each region and values in parentheses are 
absolute mitigation costs in US$. The discount rate used for the calculation is 3%. NDCs=nationally determined contributions. CAP=capability scenario. CER=constant 
emission ratios scenario. EPC=equal per capita scenario. EU-27=the 27 countries of the European Union in 2007–13. ROW=the rest of the world.
Table 3: Cumulative policy cost per region and scenario, 2020–50
Figure 3: Cumulative health co-benefits and mitigation costs by scenario, 2020–50
The discount rate used is 3%. Black uncertainty bars represent the range of values with lower and upper values of 
the VSL given in the literature.23 CAP=capability scenario. CER=constant emission ratios scenario. EPC=equal 
per capita scenario. VSL=value of statistical life.
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0% and 6% (appendix). The differences between these 
rates in terms of the shares of costs borne by the 
different regions are quite small. The 6% rate means 
future costs and benefits are both given a lower value. 
As relatively fast-growing countries in terms of GDP 
and population, such as India and China have higher 
co-benefits and potentially higher costs in the future, 
these are given a small weight with a higher discount 
rate, making their share of net costs lower at a 6% rate 
than at a 3% rate. The reverse holds for the USA. 
The EU is somewhere in between, but the difference 
between the discount rates in terms of shares is 
only 1–2%.
Figure 3 shows the monetised health co-benefits and 
mitigation costs for each scenario. Health co-benefits are 
the difference between the monetised health damage of 
each policy scenario and those in the baseline scenario. 
Notably, at the global level, the value of the health 
co-benefits is greater than the cost of achieving the 
mitigation target for all the scenarios. Indeed, there is 
one mitigation strategy, 2°C + CER, for which the co-
benefits are more than double the mitigation costs. The 
ratio of health co-benefits to mitigation costs ranges 
from 1·4 (1·5°C + CAP) to 2·45 (2°C + CER). The 
sensitivity analysis shown by the uncertainty range 
suggests that, even when taking the lower bound of VSL, 
the health co-benefits are very close to the mitigation 
cost, covering between 70–91% of that cost. For the 
non-equitable 2°C + CER scenario, even the lowest 
estimate of the health co-benefits is higher than the 
mitigation cost. It is notable that the generally higher 
value of the co-benefits in the CAP scenarios do not 
outweigh the larger policy costs, resulting in lower ratios 
of co-benefit to cost.
Figure 4 shows the regional distribution of these 
co-benefits, with most of the co-benefits located both in 
China and India. In the NDC scenario, China accounts 
for 55% of these co-benefits and India for 43%, 
respectively. In the 2°C and 1·5°C mitigation scenarios, 
they represent similar shares.
To compare co-benefits and mitigation costs for the 
different mitigation pathways, it is very useful to see 
what proportion of the additional effort of setting a more 
stringent target is compensated by the additional health 
co-benefits. This is especially important for addressing 
the objectives of the Paris Agreement to pursue efforts to 
reduce emissions to limit the temperature increase 
to 1·5°C.
It is key to analyse the policies step by step—ie, first, 
identify the effect of achieving the NDCs or the 2°C target 
(following the different defined criteria for distribution of 
mitigation efforts) compared with the baseline (no climate 
policy) scenario; then calculate, the effect of achieving the 
extra effort of the 1·5°C target instead of the 2°C target.
Figure 4: Cumulative health co-benefit per region and scenario, 2020–50
The discount rate used is 3%. NDCs=nationally determined contributions. CAP=capability scenario. CER=constant 
emission ratios scenario. EPC=equal per capita scenario. EU-27=the 27 countries of the European Union in 2007–
13. ROW=the rest of the world.
































Figure 5: Net incremental benefits by region and scenario
Data are in US$ trillion. The discount rate used is 3%. The values in parentheses are the range of results based on the lower and the upper bounds of the VSL. The first rows 
represent the net incremental results of adopting the NDCs or the 2°C stabilisation target against a baseline of no climate policy. The last rows give the net incremental 
benefits of setting the 1·5°C policy compared with the (already stablished) 2°C target. A green cell shows that, irrespective of the VSL value, the incremental health 
co-benefit is greater than the incremental mitigation cost; a yellowcell shows that whether the health co-benefits exceed the extra mitigation cost depends on the VSL 
value; and a red cell shows that the additional health co-benefits are never sufficient to cover the additional mitigation cost. VSL=value of statistical life. NDCs=nationally 
determined contributions. CAP=capability scenario. CER=constant emission ratios scenario. EPC=equal per capita scenario. EU-27=the 27 countries of the European 
Union in 2007–13. ROW=the rest of the world.
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14·49 (0·77 to 28·21)
14·89 (5·39 to 24·39)
15·22 (3·62 to 26·82)
0·27 (–1·21 to 1·75)
2·08 (–1·32 to 5·47)
2·31 (–0·05 to 4·67)
–2·70 (–3·74 to –1·67)
–0·22 (–0·60 to 0·17)
–5·33 (–5·85 to –4·81)–1·22 (–1·88 to –0·56)
–0·27 (–0·65 to 0·12)
–0·60 (–1·20 to –0·01)
–0·19 (–0·68 to 0·31)
India
5·12 (2·52 to 7·72)
26·25 (11·18 to 41·33)
23·40 (9·16 to 37·64)
19·21 (8·73 to 29·70)
3·76 (0·98 to 6·55)
3·28 (0·93 to 5·63)
8·40 (3·53 to 13·28)
ROW
Region
–0·72 (–0·38 to –1·06)
–5·01 (–8·29 to –1·73)
–4·81 (–7·32 to –2·29)
–4·42 (–7·05 to –1·79)
–6·21 (–6·83 to –5·59)
–5·92 (–6·76 to –5·08)
–3·46 (–4·32 to –2·60)
USA
–4·42 (–4·68 to –4·16)
–7·12 (–7·76 to –6·48)
–1·23 (–1·65 to –0·81)
–1·21 (–1·37 to –1·06)
–2·47 (–2·70 to –2·24)
–0·93 (–1·11 to –0·76)
Total
4·33 (–1·57 to 10·24)
25·91 (–7·84 to 59·67)
32·03 (4·97 to 59·10)
23·46 (–2·44 to 49·35)
–3·66 (–9·08 to 1·77)
–3·63 (–11·05 to 3·78)
6·14 (–2·63 to 14·90)
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Figure 5 compares the incremental health co-benefits 
with the incremental mitigation cost for a range of values 
of VSL for each of the intermediate steps. For China and 
India, the mitigation costs are compensated by the co-
benefits for a 2°C target, irrespective of the burden sharing 
approach. The extra cost of going from the 2°C to the 
1·5°C target is also always fully compensated for India, 
whereas for China it depends on the VSL chosen. The 
results in the other regions suggest that the incremental 
mitigation cost is often higher than the incremental co-
benefit. Globally, the incremental health co-benefits 
outweigh the incremental mitigation cost of a 2°C target, 
depending on the VSL value, except for CER where this is 
the case for all VSL values.
Updated emission trajectories have been used in more 
recently published GCAM scenarios,34 so we did a 
sensitivity analysis to investigate whether these changes 
affected our results. We found that the changes did not 
affect the overall conclusions of the paper, as shown in the 
appendix. Although there is emerging work investigating 
different future air pollution policy pathways,35 these will be 
analysed in future research. The impact of alternative 
socioeconomic pathways on emission trajectories is shown 
in the appendix.
Discussion
Climate change and air pollution are important, inter-
related problems. Our study is a comprehensive assessment 
of the global and regional implications of climate change 
mitigation in terms of (ambient) air pollution in the coming 
decades. The results show that, in all the scenarios, global 
health co-benefits are greater than the mitigation cost of 
achieving the target. The ratio of health co-benefit to 
mitigation cost ranges between 1·4 and 2·45. The staged 
approach, CER, is the most efficient burden sharing 
approach in terms of net cost.
Because of uncertainty over VSL values, we did a 
sensitivity analysis. The result of this analysis showed 
that, even with the lower bound of the VSL, the value of 
the health co-benefits would cover 70–91% of the 
mitigation costs, depending on the chosen scenario. 
There was one strategy, 2°C + CER, for which, the health 
co-benefits remained greater than the costs, even with 
the lower bound for VSL.
To better understand which target might be favourable 
for each region and under what burden sharing criteria, 
we did a incremental analysis, comparing the additional 
benefits of going from no target to an NDC-based target, 
from no target to a 2°C target, and from a 2°C target to a 
1·5°C target. The results showed that in China and India, 
the cost of setting any additional policy could be 
compensated just with the health benefits in most cases. 
Other regions could not compensate the costs with the co-
benefits alone, but the co-benefits would make a valuable 
contribution towards covering the mitigation costs, from 
7% to 84% in the EU-27 countries and from 10% to 41% in 
the USA. In all cases it is important to remember that 
attaining the 2°C target comes with considerable benefits 
from reduced climate change impact benefits for all 
regions, including health benefits, and attaining a 
1·5°C target has even greater climate benefits.
The study has various limitations, which we elaborate 
on in the appendix. For example, we could not include 
all of the published strategies because of modelling 
limitations (GCAM does not allow negative emissions 
to be set as regional climate targets) and we only focused 
on health damage without taking into consideration 
other potential types of damage (ie, agricultural damage 
due to ozone concentration). In particular, we wish to 
draw attention to two points. First, population project-
ions by grid cell do not allow for changes when the cell 
currently has a zero population, so we have to assume 
that no urban expansion will occur on land that is 
currently completely uninhabited. Second, the policy 
instrument we use with GCAM for the GHG reductions 
is a regional carbon tax (one per defined region), so 
further work will be needed to consider more frag-
mented instruments.
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